Bristol-Myers Squibb Company (BMY)

57.81
0.21 0.36
NYSE
Prev Close 57.60
Open 57.72
Day Low/High 57.52 / 58.16
52 Wk Low/High 56.66 / 69.75
Volume 9.68M
Exchange NYSE
Shares Outstanding 2222.11B
Market Cap 128.46B
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Don't Own Merck Stock Yet? Here's My Prescription

Don't Own Merck Stock Yet? Here's My Prescription

I am in this one for the medium to long term.

A Bristol-Myers Bounce? Here's How I'd Play It

A Bristol-Myers Bounce? Here's How I'd Play It

Keep in mind earnings are scheduled for Oct. 27 along with a $0.49 dividend on Sept. 30.

3 Big Pharma Buys for Dividend Investors

3 Big Pharma Buys for Dividend Investors

In a market with elevated valuations and low yields, we see pharmaceutical stocks as a respite from both.

Would-Be Buyers Should Wait for a Dip in Bullish Prothena

Would-Be Buyers Should Wait for a Dip in Bullish Prothena

The shares of the under-the-radar biotech have had a strong run in recent months, so traders might want to watch for a pullback to buy.

Pfizer's Charts Suggest a Strong Rally Ahead

Pfizer's Charts Suggest a Strong Rally Ahead

Here are our latest price targets.

Jim Cramer: The Drug Cos. Are at Full Strength

Jim Cramer: The Drug Cos. Are at Full Strength

We're seeing a group move in pharma right now, so let's sort it out, pill by pill.

Resilience? Stagflation Signs, Nvidia Action, Fed Hawks on Deck, Booster Rockets

Resilience? Stagflation Signs, Nvidia Action, Fed Hawks on Deck, Booster Rockets

A wall of liquidity seems to absorb every dip. But there are also enough reasons to be ever vigilant.

Jim Cramer: To Every Market Sector, Turn, Turn, Turn

Jim Cramer: To Every Market Sector, Turn, Turn, Turn

To the melody of the Byrds' famed song, I want you to know: There's a time to buy the industrials, a time to sell the banks; a time to bid for health cares, a time to dump the techs. ...

China 'Rules', Defense Stocks, Infrastructure Package, FOMC, Earnings

China 'Rules', Defense Stocks, Infrastructure Package, FOMC, Earnings

What if Beijing plays the power game with foreign firms reliant upon Chinese revenue, Chinese labor, or simply Chinese economic growth?

Bristol-Myers Squibb Makes Its Upside Breakout

Bristol-Myers Squibb Makes Its Upside Breakout

Here's what traders and investors should do next.

Here Is Something Cathie Wood and I Agree On

* The attractiveness of Coinbase  Speaking of ARK Invest, the ETF complex has purchased Coinbase on nearly three-quarters of the days it has been public. All transactions below are dated May 20: FUND Direction Ticker CUSIP Name Shares % of ETF ARKF ...

2 Biotech Stocks That Appear Undervalued Based on Their Prospects

2 Biotech Stocks That Appear Undervalued Based on Their Prospects

Agenus Inc. and uniQure N.V. recently have announced positive news developments that should boost their long-term prospects.

Jim Cramer: Here's What Can Go Higher

Jim Cramer: Here's What Can Go Higher

Let's look at the companies that can go up, and the ones that can't.

Jim Cramer: Don't Bet Against Comebacks in This Second Chance Market

Jim Cramer: Don't Bet Against Comebacks in This Second Chance Market

Just like you have to know how to read a room, you have to know how to read a tape and this tape screams 'I'm not done yet.'

Economics for Dummies, Fed Recap, Fun With Jobs Math, Amazon, Buying ServiceNow

Economics for Dummies, Fed Recap, Fun With Jobs Math, Amazon, Buying ServiceNow

The differences in approach between the two most basic strategies for how to grow an economy are as stark as the division they cause among economists.

A Blue Chip Healthcare Stock for Growth And Yield

A Blue Chip Healthcare Stock for Growth And Yield

Bristol-Myers offers a terrific combination of yield, dividend safety, and dividend growth for income-focused investors.

Is Bristol-Myers Squibb Finally Ready for a Breakout?

Is Bristol-Myers Squibb Finally Ready for a Breakout?

Prices have rallied from early March and are in a position to test their January highs.

Looking at Bristol-Myers Again as the Quants Downgrade It

Looking at Bristol-Myers Again as the Quants Downgrade It

At current levels BMY is sort-of in no man's land - not bullish and not bearish.

Here Are 2 Biotechs That Posted Strong Earnings

Here Are 2 Biotechs That Posted Strong Earnings

Exelixis and Ultragenyx Pharmaceutical are cash rich mid-caps that don't look overbought.

Turn of the Worm, Treasury Curve, Manchin's Might, Trading Microsoft, Spotify

Turn of the Worm, Treasury Curve, Manchin's Might, Trading Microsoft, Spotify

There is a point where if longer-dated yields move high enough, defensive-minded investors will be drawn from equities to debt securities.

Jim Cramer: Looking for Gold? Go With Science

Jim Cramer: Looking for Gold? Go With Science

A potential breakthrough in Alzheimer's. A new device for blood pressure. More vaccines. These are opportunities to cheer in a time of turmoil.

Bristol-Myers Squibb Could Finally Make Its Move

Bristol-Myers Squibb Could Finally Make Its Move

Traders should stay long and consider increasing their exposure.

How to Play Emergent BioSolutions Right Now

How to Play Emergent BioSolutions Right Now

A correction in EBS could soon set up an attractive opportunity.

The Week That Was, Q4 Earnings Expectations, Key Investor and Healthcare Events

The Week That Was, Q4 Earnings Expectations, Key Investor and Healthcare Events

This Friday several banks begin the unofficial kickoff of 'earnings season'.

How I'm Playing Astra-Zeneca on Vaccine and Acquisition News

How I'm Playing Astra-Zeneca on Vaccine and Acquisition News

I am staying away from this name for now, despite the Alexion acquisition and vaccine promise.

2 Potential Acquisition Targets as Biotech Deal Activity Picks Up

2 Potential Acquisition Targets as Biotech Deal Activity Picks Up

BioXcel Therapeutics and Avadel Pharmaceuticals would make good additions to the portfolios of larger drug companies.

This Trio of Diverse Stocks Makes for Interesting Stalking

This Trio of Diverse Stocks Makes for Interesting Stalking

The technical patterns of Boeing, Bristol-Myers Squibb and DraftKings are worth tracking for potential buys.